Drawbridge Pharmaceuticals Overview

  • Founded
  • 2011
Founded
  • Status
  • Private
  • Employees
  • 3
Employees
  • Latest Deal Type
  • Later Stage VC
  • (Cancelled)
  • Latest Deal Amount
  • $25M
Latest Deal Amount
  • Investors
  • 1

Drawbridge Pharmaceuticals General Information

Description

Operator of a biotechnology company intended to develop innovative neuroactive steroid compounds. The company's neuroactive steroid compound is a fast onset and offset intravenous general anaesthetic and sedative that protects the brain from the harmful effects of insults such as hypoxia and trauma, enabling doctors to reduce cardiovascular depression during the course of critical care situations.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 23 Milton Parade
  • Malvern, Victoria 3144
  • Australia
+61 (03) 0000 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Drawbridge Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC 28-Sep-2017 $25M Cancelled Clinical Trials - Phase 2
3. Angel (individual) 01-Aug-2017 00000 00.000 Completed Clinical Trials - Phase 1
2. Angel (individual) 01-Jul-2016 $1M $1M Completed Startup
1. Grant 01-Jan-2014 $2.69K Completed Startup
To view Drawbridge Pharmaceuticals’s complete valuation and funding history, request access »

Drawbridge Pharmaceuticals Patents

Drawbridge Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2019297195-A1 Neuroactive steroids and methods of preparation Pending 03-Jul-2018 000000000
EP-3818068-A1 Neuroactive steroids and methods of preparation Pending 03-Jul-2018 000000000
US-20150265632-A1 Neuroactive steroids and their use to facilitate neuroprotection Granted 09-Nov-2012 0000000000 0
US-9757391-B2 Neuroactive steroids and their use to facilitate neuroprotection Active 09-Nov-2012 0000000000
EP-2916846-A1 Neuroactive steroids and their use to facilitate neuroprotection Pending 09-Nov-2012 A61K31/573

Drawbridge Pharmaceuticals Executive Team (3)

Name Title Board Seat Contact Info
Gary Taylor Chief Financial Officer & Secretary
Juliet Goodchild Ph.D Co-founder, Chief Product Officer & Executive Director
Colin Goodchild Ph.D Co-Founder, Chairman & Chief Medical Officer
To view Drawbridge Pharmaceuticals’s complete executive team members history, request access »

Drawbridge Pharmaceuticals Board Members (2)

Name Representing Role Since
Colin Goodchild Ph.D Drawbridge Pharmaceuticals Co-Founder, Chairman & Chief Medical Officer 000 0000
David Page Drawbridge Pharmaceuticals Board Member 000 0000
To view Drawbridge Pharmaceuticals’s complete board members history, request access »

Drawbridge Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Drawbridge Pharmaceuticals Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Department of State Development, Business and Innovation Government 000 0000 000000 0
To view Drawbridge Pharmaceuticals’s complete investors history, request access »